WEBULL
WebtradeDownload

Chemours (CC) Could Be 18% Undervalued After The Class Action Shock

Simply Wall St · 1d ago

The trigger for Chemours (CC) right now is legal, not operational. A securities class action targeting alleged Opteon sales misreporting has sharpened investor focus on reporting quality and future cash flow resilience.

The legal headline hit a stock that had already been drifting, with a 90-day share price return down 8.74% even as the 1-year total shareholder return sits at 16.93%. Chemours has been volatile this year, and the recent class action appears to be reinforcing that pattern rather than starting it. Short term share price momentum has softened despite earlier support from third quarter results, earnings guidance and a reaffirmed dividend.

Scan how Chemours screens against other materials and AI infrastructure plays by running the 53 AI infrastructure stocks before this legal story drifts further from its initial shock.

Chemours now trades against fresh legal risk and a recent 19% drop, so the real choice is whether that sets up a reasonable entry today or argues for patience while the valuation case firms up.

Most Popular Narrative: 18% Undervalued

Chemours closed at $13.79 while the most followed narrative anchors fair value at $16.90, so the gap now hinges on how durable earnings and cash flows prove against refrigerant cycles and PFAS liabilities.

Execution on the Pathway to Thrive program, including guidance for adjusted EBITDA of US$775m to US$825m in 2026, a medium term target of at least US$1b adjusted EBITDA with more than 40% free cash flow conversion, and actions that have addressed close to US$2b of near term debt while aiming for net leverage around 3.8x, supports the case that Chemours can gradually improve earnings stability and free cash flow over time.

See why 13 investors see Chemours as 18% undervalued.

Result: Fair Value of $16.90 (UNDERVALUED)

Still, unresolved PFAS litigation and softer near term Thermal & Specialized Solutions demand mean Chemours faces real cash flow and earnings risk if these pressures deepen.

Find out about the key risks to this Chemours narrative.

Next Steps

Reading this, you can probably feel the split mood around Chemours, with fresh legal risk on one side and valuation support on the other. Consider acting while the data and sentiment are still shifting, and weigh both sides for yourself by checking the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Chemours?

If Chemours has your attention but you are not ready to stop at one ticker, use this moment to widen your search before the next move gets priced in.